Microbial products market players are Amgen Inc., Merck & Co., Inc., Valent BioSciences Corp., GlaxoSmithKline plc, Pfizer Inc., bioMérieux SA, Ajinomoto Co.Inc., Sanofi S.A, Novartis AG, NovaDigm Therapeutics, Kyowa Hakko Bio Co., Ltd. and others.

According to a recent study published by the Market Research Future analysts, the microbial products market is expected to reach USD 1,910 Million by 2030 at 6.20% CAGR during the forecast period 2022-2030.